NCT00211536View on ClinicalTrials.gov

Study Comparing Effectiveness of Intraperitoneal Insulin Administration to Subcutaneous Insulin Administration

PHASE3CompletedINTERVENTIONAL
Enrollment

107

Participants

Timeline

Start Date

June 30, 2002

Primary Completion Date

August 31, 2004

Study Completion Date

September 30, 2008

Conditions
Type 1 Diabetes
Interventions
DRUG

Medtronic MiniMed Implantable Pump Human Recombinant Insulin

400 IU per ml - dosage based on the Investigators clinical judgement and the individual subject requirements.

DEVICE

Medtronic MiniMed Implantable Pump System

The implantable pump system is intended to provide continuous intraperitoneal delivery of insulin in subjects with diabetes.

DRUG

Aventis HOE21PH U400

400 IU per ml - dosage based on the Investigators clinical judgement and the individual subject requirements.

Trial Locations (5)

44195

Cleveland Clinic, Wooser

64116

Hellman & Rosen Endocrine Associates, North Kansas City

78229

Diabetes & Glandular Disease Clinic, San Antonio

80010

University of Colorado Health Sciences Center, Aurora

93105

Sansum Medical Research Institute, Santa Barbara

All Listed Sponsors
lead

Medtronic Diabetes

INDUSTRY

NCT00211536 - Study Comparing Effectiveness of Intraperitoneal Insulin Administration to Subcutaneous Insulin Administration | Biotech Hunter | Biotech Hunter